Kamada's (KMDA) Inhaled Alpha-1 Antitrypsin Phase 2 Met Primary Endpoint
Tweet Send to a Friend
Kamada Ltd. (Nasdaq: KMDA) announced positive top-line results, meeting the primary endpoint of the Company’s U.S. Phase 2 clinical trial ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
